CINCINNATI--(BUSINESS WIRE)--May 15, 2018--
Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced the nomination of a new director, Cheryl Cohen, to its
Board of Directors. Ms. Cohen will stand for election at Aerpio’s 2018
Annual Meeting of Stockholders on June 20, 2018. If approved, Ms. Cohen
will bring to Aerpio more than 25 years of experience in the
biopharmaceutical industry, with a focus on strategic product
positioning and product commercialization.
“We are pleased to welcome Cheryl, who possesses deep industry expertise
in advancing innovative healthcare products through launch and
commercialization,” stated Stephen Hoffman, M.D., Ph.D., Chief Executive
Officer of Aerpio. “We believe her deep experience in product launch,
commercialization and reimbursement will be invaluable to Aerpio as we
further advance our key programs and build our proprietary product
Ms. Cohen currently serves as president of CLC Consulting, a
pharmaceutical and biotechnology consulting firm specializing in new
product start-up and commercialization, which she incorporated in 2008.
From 2011 to 2014, Ms. Cohen served as Chief Commercial Officer of
Medivation, Inc., where she established and led the company's commercial
organization and was responsible for the U.S. launch of Xtandi®
(enzalutamide) for metastatic castration-resistant prostate cancer.
Medivation was acquired by Pfizer Inc. for $14 billion in 2016. Ms.
Cohen held leadership roles for over a decade at Johnson & Johnson,
including as vice president, strategic commercial group, Health Care
Systems, Inc., responsible for the negotiations of Johnson & Johnson's
portfolio of products to ensure access and preferred positioning, and as
vice president, rheumatology franchise, Centocor, Inc., where she had
direct responsibility for the $1+ billion per year Remicade U.S.
rheumatoid arthritis business. Ms. Cohen began her career at Solvay
Pharmaceuticals in a variety of sales positions. Ms. Cohen currently
serves on the boards of directors of Novus Therapeutics, a publicly
traded company, and Vital Therapies, Inc., a public company. Ms. Cohen
received her B.A. from Saint Joseph College.
Ms. Cohen stated, “As diabetic complications continue to grow worldwide,
patients and physicians are seeking new approaches to address compelling
unmet needs. Aerpio is rapidly progressing clinical development of its
first-in-class therapeutic that I believe holds great promise in
transforming the treatment of the complications of diabetes. I look
forward to working closely with the talented team at Aerpio.”
In addition, the Company announced that effective as of the 2018 Annual
Meeting of Stockholders, Paul M. Weiss, Ph.D., will have completed his
term as an Aerpio Board member and will no longer serve as a director
for the Company.
Muneer Satter, Aerpio’s Chairman of the Board, commented, “We are
grateful to Paul Weiss for his leadership since he joined the Board in
2011. His contributions have played a key role in the progress of the
Company and the advancement of our products. We wish him well in his
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB‐9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information please
Forward Looking Statements
This press release contains forward-looking statements. Statements in
this press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other things,
the development of the Company’s product candidates, our long-term
growth, and the therapeutic potential of the Company’s product
candidates. Actual results could differ from those projected in any
forward-looking statements due to several risk factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to develop our product candidates, the inherent
uncertainties associated with the FDA and drug development process,
competition in the industry in which the Company operates, and overall
market conditions. These forward-looking statements are made as of the
date of this press release, and the Company assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all the
information set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents the Company
files with the SEC available at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180515006766/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.